Drug Profile
Research programme: anti-viral therapeutics - TGV Laboratories
Alternative Names: MV-4; T-169Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator TGV-Laboratories
- Class Antivirals; Small molecules
- Mechanism of Action Glycoprotein modulators; Phospholipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Adenovirus infections; HIV-1 infections; HIV-2 infections; Influenza virus infections; Poliomyelitis
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in HIV-1-infections in Russia (PO, Capsule)
- 28 Jun 2022 No recent reports of development identified for preclinical development in HIV-2-infections in Russia (PO, Capsule)
- 28 May 2020 No recent reports of development identified for research development in Adenovirus-infections in USA (IV)